Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Symptom Management Among Multiple Sclerosis Care Partners in Canada

View through CrossRef
CE INFORMATION ACTIVITY AVAILABLE ONLINE: To access the article and evaluation online, go to https://www.highmarksce.com/mscare. TARGET AUDIENCE: The target audience for this activity is physicians, advanced practice clinicians, nursing professionals, social workers, and other health care providers involved in the management of patients with multiple sclerosis (MS). LEARNING OBJECTIVE: Characterize the type, number, and frequency of symptoms MS care partners manage. Describe the level of symptom management difficulty in the caregiving role and types of support preferred by MS care partners. ACCREDITATION: In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Intellisphere, LLC. The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team. This activity was planned by and for the health care team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change. PHYSICIANS: The CMSC designates this journal-based activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. NURSES: The CMSC designates this enduring material for 0.5 contact hour of nursing continuing professional development (NCPD) (none in the area of pharmacology). PSYCHOLOGISTS: This activity is awarded 0.5 CE credit. SOCIAL WORKERS: As a Jointly Accredited Organization, the CMSC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 0.5 general continuing education credit. DISCLOSURES: It is the policy of the Consortium of Multiple Sclerosis Centers to mitigate all relevant financial disclosures from planners, faculty, and other persons that can affect the content of this CE activity. For this activity, all relevant disclosures have been mitigated. Francois Bethoux, MD, editor in chief of the International Journal of MS Care (IJMSC), has served as physician planner for this activity. He and Alissa Mary Willis, MD, associate editor of IJMSC, have disclosed no relevant financial relationships. Authors; Katherine L. Cardwell, BHSc; Taylor A. Hume, BHSc; Odessa J. McKenna, MSc; Lara A. Pilutti, PhD; and Afolasade Fakolade, PhD, have disclosed no relevant financial relationships. The staff at IJMSC, CMSC, and Intellisphere, LLC who are in a position to influence content have disclosed no relevant financial relationships. Laurie Scudder, DNP, NP, continuing education director CMSC, has served as a planner and reviewer for this activity. She has disclosed no relevant financial relationships. METHOD OF PARTICIPATION: Release Date: November 1, 2023; Valid for Credit through: November 1, 2024 To receive CE credit, participants must: (1) Review the continuing education information, including learning objectives and author disclosures.(2) Study the educational content.(3) Complete the evaluation, which is available at https://www.highmarksce.com/mscare. Statements of Credit are awarded upon successful completion of the evaluation. There is no fee to participate in this activity. DISCLOSURE OF UNLABELED USE: This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. The CMSC and Intellisphere, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the CMSC or Intellisphere, LLC. DISCLAIMER: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
Title: Symptom Management Among Multiple Sclerosis Care Partners in Canada
Description:
CE INFORMATION ACTIVITY AVAILABLE ONLINE: To access the article and evaluation online, go to https://www.
highmarksce.
com/mscare.
TARGET AUDIENCE: The target audience for this activity is physicians, advanced practice clinicians, nursing professionals, social workers, and other health care providers involved in the management of patients with multiple sclerosis (MS).
LEARNING OBJECTIVE: Characterize the type, number, and frequency of symptoms MS care partners manage.
Describe the level of symptom management difficulty in the caregiving role and types of support preferred by MS care partners.
ACCREDITATION: In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Intellisphere, LLC.
The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
This activity was planned by and for the health care team, and learners will receive 0.
5 Interprofessional Continuing Education (IPCE) credit for learning and change.
PHYSICIANS: The CMSC designates this journal-based activity for a maximum of 0.
5 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES: The CMSC designates this enduring material for 0.
5 contact hour of nursing continuing professional development (NCPD) (none in the area of pharmacology).
PSYCHOLOGISTS: This activity is awarded 0.
5 CE credit.
SOCIAL WORKERS: As a Jointly Accredited Organization, the CMSC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program.
Organizations, not individual courses, are approved under this program.
Regulatory boards are the final authority on courses accepted for continuing education credit.
Social workers completing this course receive 0.
5 general continuing education credit.
DISCLOSURES: It is the policy of the Consortium of Multiple Sclerosis Centers to mitigate all relevant financial disclosures from planners, faculty, and other persons that can affect the content of this CE activity.
For this activity, all relevant disclosures have been mitigated.
Francois Bethoux, MD, editor in chief of the International Journal of MS Care (IJMSC), has served as physician planner for this activity.
He and Alissa Mary Willis, MD, associate editor of IJMSC, have disclosed no relevant financial relationships.
Authors; Katherine L.
Cardwell, BHSc; Taylor A.
Hume, BHSc; Odessa J.
McKenna, MSc; Lara A.
Pilutti, PhD; and Afolasade Fakolade, PhD, have disclosed no relevant financial relationships.
The staff at IJMSC, CMSC, and Intellisphere, LLC who are in a position to influence content have disclosed no relevant financial relationships.
Laurie Scudder, DNP, NP, continuing education director CMSC, has served as a planner and reviewer for this activity.
She has disclosed no relevant financial relationships.
METHOD OF PARTICIPATION: Release Date: November 1, 2023; Valid for Credit through: November 1, 2024 To receive CE credit, participants must: (1) Review the continuing education information, including learning objectives and author disclosures.
(2) Study the educational content.
(3) Complete the evaluation, which is available at https://www.
highmarksce.
com/mscare.
Statements of Credit are awarded upon successful completion of the evaluation.
There is no fee to participate in this activity.
DISCLOSURE OF UNLABELED USE: This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
The CMSC and Intellisphere, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the CMSC or Intellisphere, LLC.
DISCLAIMER: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.
The information presented in this activity is not meant to serve as a guideline for patient management.
Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

Related Results

Multiple myeloma patients undergoing chemotherapy: Which symptom clusters impact quality of life?
Multiple myeloma patients undergoing chemotherapy: Which symptom clusters impact quality of life?
AbstractAims and ObjectivesTo identify symptom clusters and examine their association with health‐related quality of life.BackgroundMultiple myeloma patients undergoing chemotherap...
Narrative review based on fingolimod therapy in pediatric MS
Narrative review based on fingolimod therapy in pediatric MS
The course of pediatric-onset multiple sclerosis and adult multiple sclerosis shows some clinical differences. The rate of having a second attack after the first clinical event is ...
Building Primary Palliative Care Capacity Through Education at a National Level: Pallium Canada and its LEAP Courses
Building Primary Palliative Care Capacity Through Education at a National Level: Pallium Canada and its LEAP Courses
Background All the palliative care needs of a population cannot be met by specialist palliative care clinicians and teams alone. Both primary-level and specialist-level palliative ...
OCT based evaluation of retinal changes in multiple sclerosis
OCT based evaluation of retinal changes in multiple sclerosis
Background: Optical coherence tomography is a non-invasive imaging technique routinely used in ophthalmology to visualize and quantify the layers of the retina. It also provides in...
Accuracy of MRI criteria for dissemination in space for the diagnosis of multiple sclerosis in patients with clinically isolated syndromes
Accuracy of MRI criteria for dissemination in space for the diagnosis of multiple sclerosis in patients with clinically isolated syndromes
The MRI Barkhof—Tintoré criteria have proved to be highly specific for predicting conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome...
Meta‐analysis of the use of Ofatumumab in the treatment of relapsing‐remitting multiple sclerosis
Meta‐analysis of the use of Ofatumumab in the treatment of relapsing‐remitting multiple sclerosis
AbstractBackgroundOfatumumab is the first monoclonal antibody developed specifically for treating relapsed multiple sclerosis (RMS). This disease (Multiple Sclerosis) includes rela...
Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment
Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment
Multiple sclerosis is a progressive demyelinating central nervous system disorder with unknown etiology. The condition has heterogeneous presentations, including relapsing-remittin...
Symptom clusters in patients receiving chemotherapy: A systematic review
Symptom clusters in patients receiving chemotherapy: A systematic review
Background and purposeSince 2001, symptom cluster research has grown considerably. However, because multiple methodological considerations remain, ongoing synthesis of the literatu...

Back to Top